GlassScriptPhysician profile
Lana L Milton
NPI 1760493308
$27,420.90
in general payments reported to CMS, 2019-2025
28 companies · $1,516 in 2025
The $1,516 reported for 2025 was more than what 86% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,570 · 2020: $4,441 · 2021: $6,898 · 2022: $5,041 · 2023: $2,202 · 2024: $1,752 · 2025: $1,516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,471.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,470.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $6,440.46 | 2019-2020 | |
| Abbvie INC. | $4,705.10 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $2,444.13 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Neurocrine Biosciences, INC. | $1,999.22 | 2019-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $1,869.12 | 2019-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,843.42 | 2021-2025 | Caplyta |
| Alkermes, INC. | $1,384.93 | 2019-2025 | Lybalvi, Aristada |
| Otsuka America Pharmaceutical, INC. | $974.66 | 2019-2023 | Rexulti, Abilify Maintena |
| Supernus Pharmaceuticals, INC. | $837.65 | 2021-2024 | Qelbree |
| Vanda Pharmaceuticals INC. | $806.50 | 2019-2024 | Fanapt |
| Sunovion Pharmaceuticals INC. | $606.58 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $485.54 | 2019-2022 | |
| Axsome Therapeutics, INC. | $474.44 | 2022-2025 | Auvelity |
| Lundbeck LLC | $469.82 | 2019-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $381.63 | 2024-2025 | Cobenfy |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $293.26 | 2019-2022 | |
| Eisai INC. | $254.20 | 2021-2022 | |
| Almatica Pharma LLC | $238.45 | 2021-2023 | Sertraline Hcl, Loreev Xr |
| Harmony Biosciences LLC | $144.32 | 2022 | |
| Idorsia Pharmaceuticals US INC | $142.34 | 2023 | Quviviq |
| Ironshore Pharmaceuticals INC. | $142.26 | 2019 | |
| Bausch Health US, LLC | $131.99 | 2020-2023 | Aplenzin |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $128.96 | 2022-2025 | Rejoyn |
| Acadia Pharmaceuticals INC | $124.95 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $29.97 | 2022 | |
| Merck Sharp & Dohme LLC | $24.74 | 2021 | |
| Jazz Pharmaceuticals INC. | $23.66 | 2021 | |
| Adlon Therapeutics L.P. | $18.60 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lana Milton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.